Is there a generic for Deferoxamine mesylate?

Yes. The FDA Orange Book lists 5 approved generic (ANDA) applications for Deferoxamine mesylate, referencing the brand DESFERAL. Generics rated with an "A" therapeutic-equivalence code are considered substitutable for the brand.

What is the reference-listed drug for Deferoxamine mesylate?

DESFERAL (NDA 016267, MITEM PHARMA) is the reference-listed drug — the approved product a generic applicant must show its version is the same as.

What dosage forms of Deferoxamine mesylate are approved?

Deferoxamine mesylate is approved in the following dosage form: injectable.

FDA Orange Book · active-ingredient family

Deferoxamine mesylate

Deferoxamine mesylate is approved as 1 brand and 5 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:DESFERAL · NDA 016267

Brand (NDA)

Generics (ANDA)

Listed patents

Exclusivity periods

Brand (NDA) products · injectable

Product	Applicant	Application	TE	Approved
DESFERALRLD×2	MITEM PHARMA	NDA 016267	—	May 25, 2000

Generic (ANDA) products (5)

Product	Applicant	Application	TE	Approved
DEFEROXAMINE MESYLATE×2	GLAND	ANDA 207384	AP	Sep 29, 2017
DEFEROXAMINE MESYLATE×2	FRESENIUS KABI USA	ANDA 078718	AP	Sep 15, 2009
DEFEROXAMINE MESYLATE×2	HIKMA	ANDA 078086	—	May 30, 2007
DEFEROXAMINE MESYLATE×2	DR REDDYS	ANDA 076806	—	Mar 31, 2006
DEFEROXAMINE MESYLATE×2	HOSPIRA	ANDA 076019	AP	Mar 17, 2004

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Deferoxamine mesylate — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo